SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump For President

Trump Crypto is trending amidst community discussions about its volatile performance and potential connection to broader market events, with some users highlighting its significant decline since inception and others speculating on future rallies.  The conversation includes opinions on its association with political figures and comparisons to other cryptocurrencies. Some investors discuss its possible use during this political cycle.

Avidity Biosciences, Inc. engages in the development of a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOC). It utilizes its AOC platform to design, engineer, and develop therapeutics that combine the tissue selectivity of monoclonal antibodies and the precision of oligonucleotide-based therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. The company was founded by Troy E. Wilson, Kent Hawryluk, Mark E. Davis, and Francis Patrick McCormick on November 13, 2012 and is headquartered in San Diego, CA.

Avidity Biosciences Inc

Avidity Biosciences ($RNA) is trending as community members discuss the possibility of a buyout, with some speculating on potential suitors and ideal acquisition prices. Positive data readouts and analyst target upgrades are also fueling optimism. However, news of a recent public offering has sparked debate about its implications for a potential deal and the company's financial strategy.

WorldFinancial

WorldFinancial (WLFI) is trending amid discussions about its potential as a tokenized asset platform and its association with prominent figures. Community members are debating the coin's fundamentals, future utility, and possible price movements, with some drawing comparisons to other cryptocurrencies. Bullish sentiment centers on upcoming catalysts and the broader crypto market, while bears cite centralization and governance concerns.

Teradyne, Inc. engages in the development and sale of automatic test systems. It operates through the following business segments: Semiconductor Test, Robotics, and All Other. The Semiconductor Test segment designs, manufactures, and markets semiconductor test products and services. The Robotics segment includes operations related to the design, manufacturing, and marketing of collaborative robotic arms, autonomous mobile robots, and advanced robotic control software. The company was founded by Alexander V. d'Arbeloff and Nicholas DeWolf in 1960 and is headquartered in North Reading, MA.

Teradyne, Inc.

Teradyne ($TER) is trending as investors anticipate upcoming earnings results and evaluate the company's potential to capitalize on AI compute demand. Community discussions revolve around whether AI-driven growth can offset potential weakness in other sectors like robotics. Recent analyst activity is mixed, with some firms adjusting price targets and ratings, reflecting uncertainty about Teradyne's near-term performance amid broader semiconductor industry dynamics.

Just a dead guy

DEADGUY is trending as the community highlights the token's contract address and increasing holder count. Some users are comparing it to other tokens, speculating on potential market cap growth. The coin is also gaining traction on platforms like Phantom Wallet.

Direxion Shares ETF Trust - Direxion Daily S&P Biotech Bull 3X Shares

Direxion Daily S&P Biotech Bull 3X Shares

LABU is trending as the biotech sector shows signs of recovery, with traders closely watching for a breakout above key resistance levels and potential catalysts. Community members are actively discussing potential FDA approvals and merger/acquisition (M&A) activity within the sector, while also weighing broader market conditions and the potential impact of tariffs. Some are noting the relative underperformance of biotech compared to other sectors, suggesting a possible catch-up rally.

Tidal Trust III - Fundstrat Granny Shots US Large Cap ETF

Fundstrat Granny Shots US Large Cap ETF

The Fundstrat Granny Shots US Large Cap ETF ($GRNY) is trending as investors discuss its performance and unique investment strategy, referencing analyst Tom Lee's insights. Community members are actively suggesting new additions to the ETF's holdings, while also evaluating its expense ratio and potential for long-term growth within the large-cap space.

Pump.fun

$PUMP is trending amidst community excitement and discussion around its potential within the Solana meme coin ecosystem. Conversations highlight the strength and dedication of the $WAGMI community, with many expressing long-term bullish sentiment. The community is focused on weathering market fluctuations and building a strong foundation for future growth on the $SOL network.

Kornit Digital Ltd. is engaged in the development, designing, manufacture, and marketing of industrial and commercial printing solutions for the garment, apparel, and textile industries. It offers printing solutions for apparel, polyester, sportswear, beachwear, accessories, paradigm shirt, textiles, curtains, cushions and couches. The company was founded by Ofer Ben-Zur on January 16, 2002 and is headquartered in Rosh HaAyin, Israel.

Kornit Digital Ltd

Kornit Digital is trending as investors discuss a recently disclosed 5% stake by BlackRock and the potential for a Q3 earnings beat. Community members are speculating about possible buybacks and highlighting the company's cash-rich balance sheet. Technical analysis suggests a reversal of a downtrend, contributing to the increased attention.

Zcash is a decentralized and open-source cryptocurrency that offers privacy and selective transparency of transactions. Zcash payments are published on a public blockchain, but the sender, recipient, and amount of a transaction remain private.  Zcash is based on peer-reviewed cryptographic research, and built by a security-specialized engineering team on an open source platform based on Bitcoin Core's battle-tested codebase. Our improvement over Bitcoin is the addition of privacy. Zcash uses advanced cryptographic techniques, namely zero-knowledge proofs, to guarantee the validity of transactions without revealing additional information about them.  How Zcash works  Zcash encrypts the contents of shielded transactions. Since the payment information is encrypted, the protocol uses a novel cryptographic method to verify their validity.  Zcash uses a zero-knowledge proof construction called a zk-SNARK, developed by our team of experienced cryptographers based on recent breakthroughs in cryptography. These constructions allow the network to maintain a secure ledger of balances without disclosing the parties or amounts involved. Instead of publicly demonstrating spend-authority and transaction values, the transaction metadata is encrypted and zk-SNARKs are used to prove that nobody is cheating or stealing.  Zcash also enables users to send public payments which work similarly to Bitcoin. With the support for both shielded and transparent addresses, users can choose to send Zcash privately or publicly. Zcash payments sent from a shielded address to a transparent address reveal the received balance, while payments from a transparent address to a shielded address protect the receiving value.   Check out CoinBureau for guide on What is ZCash.

Zcash

Zcash is trending amid community excitement over its recent price surge and potential as a privacy-focused alternative to Bitcoin, with some drawing attention to its limited supply. Discussions include speculation about potential listings on platforms like Robinhood and comparisons to other privacy coins. An advisor to a former POTUS tweeting positively about the token appears to be a catalyst.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma PR Newswire PRINCETON, N.J...

Shares of Soligenix rallied sharply on Tuesday, marking their best performance in nearly two months, after the biopharmaceutical company reported a key safety milestone in its confirmatory Phase 3 FLASH2 trial evaluating HyBryte (synthetic hypericin) for treating cutaneous T-cell lymphoma (CTCL).The stock jumped 20% to $1.64 on Tuesday, and added another 0.9% after hours in continued upbeat trading.The company said its first Data Monitoring Committee (DMC) meeting for the study concluded that there were no safety concerns, with HyBryte’s safety profile consistent with prior trials.&nbsp;The committee’s conclusion allows the trial to move ahead as planned, with enrollment proceeding well and an update expected in the fourth quarter of 2025, followed by a blinded interim efficacy analysis in the first half of 2026.The ongoing FLASH2 trial is a randomized, double-blind, placebo-controlled, multicenter study enrolling about 80 patients with early-stage CTCL. The study builds on Soligenix’s previous successful Phase 3 FLASH trial, which showed a 49% treatment response after 18 weeks of therapy.&nbsp;FLASH2 extends continuous double-blind treatment to 18 weeks, designed to demonstrate the drug’s effect over a more “real-world” course.HyBryte, which uses visible light-activated synthetic hypericin applied topically to skin lesions, has received orphan drug and fast-track designations from the FDA, along with&nbsp;an orphan designation from the European Medicines Agency (EMA). The company stated that its light-activated mechanism enables deeper penetration into skin tissue without causing DNA damage, positioning it as a potentially safer frontline therapy for CTCL.On Stocktwits, retail sentiment for Soligenix was ‘extremely bullish’ amid a 2,025% surge in 24-hour message volume.One bullish user described the latest Soligenix update as a strong catalyst, saying the stock appeared ready to rebound sharply after the morning dip and could test new highs in the coming sessions.&nbsp;<stembedurl>https://stocktwits.com/LithiumMakesMeHard/message/631396013</stembedurl>Another bullish user noted that the price action suggested momentum might continue, with potential for a multiday run.<stembedurl>https://stocktwits.com/bzspy/message/631352248</stembedurl><a href="https://stocktwits.com/symbol/SNGX">Soligenix’s stock</a> has declined 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Soligenix’s stock (SNGX) has declined 39% so far in 2025. (Photo credit: Getty Images)

Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally

The company said enrollment in its Phase 3 HyBryte study is progressing well, with an interim efficacy analysis planned for the first half of 2026. 

Equity

Soligenix to Present at BIO CEO & Investor Conference

Soligenix to Present at BIO CEO & Investor Conference Soligenix to Present at BIO CEO & Investor Conference PR Newswire PRINCETON, N.J., Feb. 4, 2025 PRINCETON, N.J., Feb. 4, 2025 /PRNewswire...

Soligenix to Present at Upcoming Investor Conferences

Soligenix to Present at Upcoming Investor Conferences Soligenix to Present at Upcoming Investor Conferences PR Newswire PRINCETON, N.J., Jan. 16, 2025 PRINCETON, N.J., Jan. 16, 2025 /PRNewswire...

HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma

HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma HyBryte Expanded Treatment Continues to Demonstrate Positive Outcomes in Early-Stage...

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment...

HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment

HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment HyBryte Clinical Results Demonstrate Continued Improvement Post-Treatment PR Newswire PRINCETON, N.J., Dec. 2, 2024...

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell Lymphoma PR...

Soligenix Kickstarts Dusquetide Mid-Stage Study For Patients With Inflamed Blood Vessels

Soligenix starts Phase 2 trial of SGX945 for Beh et's Disease, aiming to enroll 25 patients and report results by mid-2025. Trial includes efficacy assessments.
read more...

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin

Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin Soligenix Receives Hong Kong Patent for Improved Production of Synthetic Hypericin PR Newswire PRINCETON, N.J., Oct...

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Soligenix Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

SNGX
Soligenix Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest SNGX News

SNGXSoligenix Inc